New immune connections in osteoclast formation

Annals of the New York Academy of Sciences

Volumn 1192, Issue , 2010, Pages 117-123

  Takayanagi, Hiroshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Cathepsin K; NFATc1; Osteoclast; RANKL; T cells

Indexed keywords

CATHEPSIN K; CYTOKINE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN TYROSINE KINASE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TOLL LIKE RECEPTOR;

B LYMPHOCYTE; BONE DESTRUCTION; CELL LINEAGE; CONFERENCE PAPER; DENDRITIC CELL; IMMUNOCOMPETENT CELL; MACROPHAGE; MOLECULAR INTERACTION; MONOCYTE; NONHUMAN; OSTEOCLAST; PATHOGENESIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSCRIPTION REGULATION;

EID: 77950654521     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05303.x     Document Type: Conference Paper

References (30)

1. Horton, J.E., L.G. Raisz, H.A. Simmons, et al. 1972. Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes. Science 177: 793-795.
2. Mundy, G.R., L.G. Raisz, R.A. Cooper, et al. 1974. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N. Engl. J. Med. 291: 1041-1046.
3. Dewhirst, F.E., P.P. Stashenko, J.E. Mole & T. Tsurumachi. 1985. Purification and partial sequence of human osteoclast-activating factor: identitywith interleukin 1. J. Immunol. 135: 2562-2568.
4. Kong, Y.Y. et al. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402: 304-309.
5. Takayanagi, H. et al. 2000. T cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408: 600-605.
6. Sato,K. et al. 2006. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203: 2673-2682.
7. Takayanagi, H. 2007 Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7: 292-304.
8. Lomaga, M.A. et al. 1999. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes. Dev. 13: 1015-1024.
9. Naito, A. et al. 1999. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4: 353-362.
10. Franzoso, G. et al. 1997. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 11, 3482-3496.
11. Iotsova, V. et al. 1997. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat. Med. 3: 1285-1289.
12. Kobayashi, N. et al. 2001. Segregation of TRAF6- mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J. 20: 1271-1280.
13. Gohda, J. et al. 2005. RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J. 24: 790-799.
14. Wada, T. et al. 2005. The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nat. Med. 11: 394-399.
15. Ross, F.P.&S.L. Teitelbaum. 2005. αvβ3 andmacrophage colony-stimulating factor: partners in osteoclast biology. Immunol. Rev. 208: 88-105.
16. Lam, J. et al. 2000. TNF-αinduces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106: 1481-1488.
17. Li, P. et al. 2004. RANK signaling is not required for TNFα-mediated increase in CD11hi osteoclast precursors but is essential for mature osteoclast formation in TNFα-mediated inflammatory arthritis. J. Bone Miner. Res. 19: 207-213.
18. Kim, N. et al. 2005. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J .Exp. Med. 202: 589-595.
19. Takayanagi, H. et al. 2002. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 416: 744-749.
20. Wagner, E.F. & R. Eferl. 2005. Fos/AP-1 proteins in bone and the immune system. Immunol. Rev. 208: 126-140.
21. Sato, K. et al. 2006. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat. Med. 12: 1410-1416.
22. Yamashita, T. et al. 2007. NF-κB p50 and p52 regulate receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J. Biol. Chem. 282: 18245-18253.
23. Takayanagi, H. et al. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling for terminal differentiation of osteoclasts. Dev. Cell 3: 889-901.
24. Asagiri, M. et al. 2005. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202: 1261-1269.
25. Kim, N.,M. Takami, J. Rho, et al. 2002. A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J. Exp. Med. 195: 201-209.
26. Koga, T. et al. 2004. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428: 758-763.
27. Kaifu, T. et al. 2003. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12- deficient mice. J. Clin. Invest. 111: 323-332.
28. Mocsai, A. et al. 2004. The immunomodulatory adapter proteinsDAP12 and Fc receptorγ-chain (FcRγ) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc. Natl. Acad. Sci. USA 101: 6158-6163.
29. Shinohara, M. et al. 2008. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 132: 794-806.
30. Asagiri, M. et al. 2008. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science 319: 624-627.